Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma

Published:2014-05-09 Issue:1 Volume:12 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Roehnisch Tim,Then Cornelia,Nagel Wolfgang,Blumenthal Christina,Braciak Todd,Donzeau Mariel,Böhm Thomas,Flaig Michael,Bourquin Carole,Oduncu Fuat S

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://link.springer.com/content/pdf/10.1186/1479-5876-12-119.pdf

Reference43 articles.

1. Maloney DG: Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012, 366: 2008-2016. 10.1056/NEJMct1114348.

2. Lopez-Requena A, Burrone OR, Cesco-Gaspere M: Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Front Oncol. 2012, 2: 159-

3. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999, 5: 1171-1177. 10.1038/13928.

4. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R: Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004, 22: 4717-4724. 10.1200/JCO.2004.06.003.

5. Bendandi M: Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer. 2009, 9: 675-681. 10.1038/nrc2717.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and challenges in anti-cancer vaccines for multiple myeloma;Frontiers in Immunology;2024-08-01

2. Engineered Bacteriophage-Based In Situ Vaccine Remodels a Tumor Microenvironment and Elicits Potent Antitumor Immunity;ACS Nano;2024-05-01

3. An Engineered M13 Filamentous Nanoparticle as an Antigen Carrier for a Malignant Melanoma Immunotherapeutic Strategy;Viruses;2024-02-01

4. A Bacteriophage Cocktail TargetingYersinia pestisProvides Strong Post-Exposure Protection in a Rat Pneumonic Plague Model;2024-01-18

5. Recent Progress in Phage‐Based Nanoplatforms for Tumor Therapy;Small;2023-10-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3